Navigation Links
Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia

positive and negative subscales and the Clinical Global Impression of Improvement (CGI-I) scale. Important safety measures included incidence of adverse events, discontinuation from study due to adverse events, and laboratory measures.

Approximately 85 percent of 302 randomized patients completed this six- week study (83 percent of aripiprazole- and 90 percent of placebo-treated patients). Both doses of aripiprazole demonstrated improvement compared to placebo (p-value less than 0.05) in the mean change from baseline in PANSS Total Score at week six (aripiprazole 10 mg: -26.7; aripiprazole 30 mg: -28.6; placebo: -21.2).

The mean change from baseline to endpoint on PANSS Positive Subscale was: -7.6 for aripiprazole 10 mg (p-value less than 0.05), -8.1 for aripiprazole 30 mg (p-value less than 0.01), and -5.6 for placebo. The mean change from baseline to endpoint on PANSS Negative Subscale was: -6.9 for aripiprazole 10 mg (p-value less than 0.05), -6.6 for aripiprazole 30 mg, and -5.4 for placebo. Improvements were observed in CGI-I [aripiprazole 10 mg: 2.7 (p- value less than 0.05); aripiprazole 30 mg: 2.5 (p-value less than 0.01); placebo: 3.1].

In this study, the overall incidence of discontinuation due to adverse events was 4.3 percent for all treatment groups (5.4 percent of aripiprazole- and 2 percent of placebo-treated patients). The most common adverse events associated with aripiprazole (greater than 5 percent and at least twice the incidence compared to placebo) were extrapyramidal disorder (aripiprazole 10 mg: 13 percent; aripiprazole 30 mg: 21.6 percent; placebo: 5 percent), somnolence (aripiprazole 10 mg: 11 percent; aripiprazole 30 mg: 21.6 percent; placebo: 6 percent), and tremor (aripiprazole 10 mg: 2 percent; aripiprazole 30 mg: 11.8 percent; placebo: 2 percent).

No significant differences were found between aripiprazole and placebo on the Abnormal Involuntary Movement Scale (AIMS) or Barnes Akathisia Rating Scale (BARS). S
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:7/2/2015)... FORT LAUDERDALE, Fla. , July 2, 2015 ... & Co., is pleased to announce that its ... Inc. ("Insight Beverages") to Kerry Group plc (ISE: ... focused on taste and nutrition systems, as well ... food, beverage and pharmaceutical markets. Farlie Turner served ...
(Date:7/2/2015)... July 2, 2015 Releases of ... Aedes aegypti , , reduced the dengue ... Brazil by 95%, well below the modelled ... http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected Tropical ... Oxitec,s genetically engineered mosquitoes. The results showed that in ...
(Date:7/2/2015)... According to a new market research report " ... Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, Epilepsy, Ischemia, ... the global Neuromodulation Market is estimated at $3.65 Billion in ... at a CAGR of 11.2% during the forecast period. ... market data T ables and 32 ...
Breaking Medicine Technology:Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:7/4/2015)... ... , ... When a hacker gains access to someone’s email account, it can lead to all ... 1st, the FTC issued a scam alert about a social engineering scam which ... password reset instigated by the hacker. All they have to do is click for ...
(Date:7/3/2015)... Angeles, CA (PRWEB) , ... July 03, 2015 ... ... was opened for enrollment on July 2nd creating a buzz of media attention. ... has been published online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people ...
(Date:7/3/2015)... ... ... Scientists at several top US cancer centers believe they now know why certain ... to read the complete story , just posted on the Surviving Mesothelioma website. ... New York University exposed mice with a mutation on the tumor suppressor gene called ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief nursing ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing ... their existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, ... news , offering timely lawsuit updates and ovarian cancer warning information. The site is ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3
... have identified childhood cancer survivors who are at ... due to the lifesaving bone marrow transplants they ... need for long-term monitoring and early intervention, particularly ... education, researchers said. Among the measures investigators recommend ...
... WASHINGTON, D.C. A scientifically-based tool developed by researchers ... women prevent pregnancy naturally, is now being used by ... An estimated twenty percent of women who wish ... know when they are fertile, according to the American ...
... ... the Socially Responsible (SRI) Bullion Fund Deploy Equity Long/Short Strategy with Apple ... companies with good bottom up fundamentals and sell closely related companies that ... to the overall markets. In this case, we go long an equally ...
... ... #1 brand in designer fashion shaping swimwear, has launched a line ... shaping construction. In launching this new collection, Miraclebody® announces a ... who can nominate themselves or others, this contest will honor and ...
... when green-eyed monster took over, study found , THURSDAY, April ... jealousy, according to a new study. , Researchers had heterosexual ... was told to look for pictures of landscapes amid rapidly ... upsetting image. , At the same time, her male partner ...
... ... ... Genesys Physician Hospital Organization (PHO) was faced with the challenging decision of building a ... careful cost analysis and evaluation of possible data centers, Genesys PHO choose colocation with ...
Cached Medicine News:Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 2Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 3Health News:Getting the bead on conception 2Health News:Getting the bead on conception 3Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 2Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 3Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 4Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 5Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 6Health News:Innovative Patent-pending Shapewear Technology Introduced for Jeans. 2Health News:Genesys PHO Outsources Data Center to Online Tech 2Health News:Genesys PHO Outsources Data Center to Online Tech 3Health News:Genesys PHO Outsources Data Center to Online Tech 4
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
... securely in place. Soft strap features an ... Soft compliant foam laminate with elastic adjustment ... edema while still providing a snug fit. ... helps prevent sliding and patient irritation, and ...
... Percutaneous Dilation Tracheostomy Kits allow ... tracheostomy tube using the widely ... of a single-stage curved dilator. ... without the Portex® Blue Line ...
... Self-contained kits provide convenience and cost control. ... care trays offer a variety of wound ... management of the tracheostomized patient. , ... and trays with disposable inner cannula for ...
Medicine Products: